Treatment-resistant anxiety disorders
The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.
Abstract
Several epidemiological studies confirmed that Anxiety Disorders as a group are the most prevalent psychiatric conditions in the United States. The importance of these conditions is underlined by the fact that they cause significant disability, poor quality of life, alcohol and drug abuse. Anxiety disorders are treatable conditions and respond to the front-line interventions such as serotonin reuptake inhibitors and cognitive behavioral therapy. However, only about 60% of patients respond to those treatments to any significant degree. Many still have residual symptoms or stay treatment refractory. The group of anxiety patients that is resistant to the treatment has been shown to have very poor quality of life and have highest rate of suicidal attempts than any other disorders. Many biological, treatment specific and social factors are affecting treatment resistance. In this paper, we are attempting to review reasons for the treatment resistance. In addition, we would like to review current strategies that could be helpful in reducing treatment resistance and aiding people chronically suffering from these severe and disabling conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Several factors are associated with treatment-resistant anxiety, including comorbid physical and mental health conditions, noncompliance and environmental stressors.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Physical and mental health comorbidity (e.g.depression, other anxiety disorders, personality disorders, mild cognitive deficits, physical ill-health, pain) is common in TR-GAD and is associated with poor treatment response.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Although treatment for anxiety disorders produces moderate QOL improvements, not all individuals respond to these front-line interventions, and those who are treatment refractory exhibit particularly low QOL and increased rates of suicide [85].”
From Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research (2021) · cites this paper as [85]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
The Emotional Brain, Fear, and the Amygdala
LeDoux, J. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025048802629 · Cited by 1,818
Neuroanatomical Hypothesis of Panic Disorder, Revised
Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.493 · Cited by 1,004
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Neuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831
Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy
Morris, G. L., Mueller, W. M., & The Vagus Nerve Stimulation Study Group E–E (1999) · Neurology · doi:10.1212/wnl.53.8.1731 · Cited by 724
Groves, D. A., & Brown, V. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.01.004 · Cited by 675
Research works printed but not linked: 5
- Nemeroff CB . Remission: today's target in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2002; 36: 5.
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D . Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long term studies. J Clin Psychopharmacol 2003; 23: 250–259.
- Barlow DH, Gorman JM, Shear MK, Woods SW . Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 283: 2529–2536. · DOI · Paper page
- Beale MD, Kellner CH, Pritchett JT, Burns CM . ECT for OCD. J Clin Psychiatry 1995; 56: 81–82.
- Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347–354. · DOI · Paper page
Cited by
Frontal midline theta reflects anxiety and cognitive control: Meta-analytic evidence
Cavanagh, J. F., & Shackman, A. J. (2015) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2014.04.003 · Cited by 623
“These psychiatric disorders are highly prevalent, debilitating, and challenging to treat (Bystritsky, 2006; Kessler et al., 2012), underscoring the importance of a deeper understanding of the neural systems that confer liability to dispositional anxiety.”
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Activation of β-catenin by carcinogenic Helicobacter pylori
Franco, A. T., Israel, D. A., Washington, M. K., Krishna, U., Fox, J. G., Rogers, A. B., Neish, A. S., Collier-Hyams, L., Perez-Perez, G. I., Hatakeyama, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504927102 · Cited by 479
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“The literature, however, indicates that only 60–85% of patients with anxiety disorders respond (experience at least a 50% improvement) to current biological and psychological treatments (6).”
BackgroundCandidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Contributions of the central extended amygdala to fear and anxiety
Shackman, A. J., & Fox, A. S. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0982-16.2016 · Cited by 269
“Existing treatments are inconsistently effective or associated with significant adverse effects (Bystritsky, 2006; Insel, 2012; Griebel and Holmes, 2013), underscoring the need to develop a deeper understanding of the neural circuits that control the experience and expression of fear and anxiety in…”
BackgroundCurrent diagnosis and treatment of anxiety disorders.
Bystritsky, A., Khalsa, S. S., Cameron, M., & Schiffman, J. E. (2013) · Europe PMC (PubMed Central) · Cited by 397
Self-citationCostello, H., Gould, R. L., Abrol, E., & Howard, R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027925 · Cited by 248
“16 However, only 60% of patients are thought to respond to pharmacological and psychological treatments, and understanding of the underlying pathophysiological mechanisms of anxiety disorders remains poor.(17) Generalised anxiety disorder (GAD) is the most common anxiety disorder, with a degree of associated disabilit…”
BackgroundDispositional negativity: An integrative psychological and neurobiological perspective.
Shackman, A. J., Tromp, D. P. M., Stockbridge, M. D., Kaplan, C. M., Tillman, R. M., & Fox, A. S. (2016) · Psychological Bulletin · doi:10.1037/bul0000073 · Cited by 234
“Wilson, Vaidyanathan, Miller, McGue, & Iacono, 2014)—psychiatric disorders that are highly prevalent, debilitating, and often challenging to treat (Bystritsky, 2006; Collins et al., 2011; DiLuca & Olesen, 2014; Griebel & Holmes, 2013; Insel, 2012; Kessler, Petukhova, Sampson, Zaslavsky, & Wittchen, 2012; Whiteford et…”
Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders
Schiele, M. A., & Domschke, K. (2018) · Genes, Brain and Behavior · doi:10.1111/gbb.12423 · Cited by 233
“This is of particular relevance given the fact that 20–40% of patients with anxiety disorders do not respond sufficiently to the initial mode of treatment (Bystritsky 2006), which is associated with poor quality of life, high rates of suicidal attempts and considerable socioeconomic consequences as detailed above (Ole…”
BackgroundBradley, P., Shiekh, M., Mehra, V., Vrbicky, K., Layle, S., Olson, M. C., Maciel, A., Cullors, A., Garces, J. A., & Lukowiak, A. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.09.024 · Cited by 222
Zebrafish models in neuropsychopharmacology and CNS drug discovery
Khan, K. M., Collier, A. D., Meshalkina, D. A., Kysil, E. V., Khatsko, S. L., Kolesnikova, T., Morzherin, Y. Y., Warnick, J. E., Kalueff, A. V., & Echevarria, D. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13754 · Cited by 204
“The first line of treatment for anxiety disorders is typically a regimen of SSRIs or cognitive behavioural therapy (Bystritsky, 2006).”
BackgroundInfluentialFox, A. S., & Shackman, A. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.056 · Cited by 194
“Existing treatments are inconsistently effective or associated with significant adverse effects [5,6], underscoring the need to develop a deeper understanding of the distributed neural circuits that control the expression of fear and anxiety.”
Ziegler, C., Richter, J., Mahr, M., Gajewska, A., Schiele, M. A., Gehrmann, A., Schmidt, B., Lesch, K.-P., Lang, T., Helbig-Lang, S., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.41 · Cited by 183
Evolutionarily conserved prefrontal-amygdalar dysfunction in early-life anxiety
Birn, R. M., Shackman, A. J., Oler, J. A., Williams, L. E., McFarlin, D. R., Rogers, G. M., Shelton, S. E., Alexander, A. L., Pine, D. S., Slattery, M. J., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.46 · Cited by 159
Anxiety and Brain Mitochondria: A Bidirectional Crosstalk
Filiou, M. D., & Sandi, C. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.07.002 · Cited by 161
Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research
Wilmer, M. T., Anderson, K., & Reynolds, M. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01290-4 · Cited by 150
Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal
Distler, M. G., Plant, L. D., Sokoloff, G., Hawk, A. J., Aneas, I., Wuenschell, G. E., Termini, J., Meredith, S. C., Nobrega, M. A., & Palmer, A. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61319 · Cited by 146
“Anxiety disorders, such as post-traumatic stress disorder, panic disorder, social phobia, specific phobia, and generalized anxiety disorder, comprise the most common psychiatric diseases in the United States (1).”
Kredlow, M. A., Unger, L. D., & Otto, M. W. (2016) · Psychological Bulletin · doi:10.1037/bul0000034 · Cited by 130
“Yet, despite the relative efficacy of exposure-based interventions for anxiety (Hofmann & Smits, 2008; Olatunji, Cisler, & Deacon, 2010) and trauma-related disorders (Powers, Halpern, Ferenschak, Gillihan, & Foa, 2010), there remains a large percentage of individuals who do not respond to, relapse after, or drop out o…”
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders
Leonard, S. K., Dwyer, J. M., Rizzo, S. J. S., Platt, B. J., Logue, S. F., Webb, S. J. N., Malberg, J. E., Beyer, C. E., Schechter, L. E., Rosenzweig-Lipson, S. J., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1080-4 · Cited by 148
Re-evaluating the link between neuropsychiatric disorders and dysregulated adult neurogenesis
Yun, S., Reynolds, R. P., Masiulis, I., & Eisch, A. J. (2016) · Nature Medicine · doi:10.1038/nm.4218 · Cited by 128
Fox, A. S., Oler, J. A., Birn, R. M., Shackman, A. J., Alexander, A. L., & Kalin, N. H. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0102-18.2018 · Cited by 127
Neural circuitry governing anxious individuals’ mis-allocation of working memory to threat
Stout, D. M., Shackman, A. J., Pedersen, W. S., Miskovich, T. A., & Larson, C. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-08443-7 · Cited by 126
Neural mechanisms underlying heterogeneity in the presentation of anxious temperament
Shackman, A. J., Fox, A. S., Oler, J. A., Shelton, S. E., Davidson, R. J., & Kalin, N. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214364110 · Cited by 113
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
Wang, L. A., de Kloet, A. D., Pati, D., Hiller, H., Smith, J. A., Pioquinto, D. J., Ludin, J. A., Oh, S. P., Katovich, M. J., Frazier, C. J., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.026 · Cited by 106
“Despite therapeutic advancements, it is estimated that 40% of patients with anxiety disorders are resistant to treatment (Bystritsky, 2006).”
Fernández‐Aranda, F., Treasure, J., Paslakis, G., Agüera, Z., Giménez, M., Granero, R., Sánchez, I., Serrano‐Troncoso, E., Gorwood, P., Herpertz‐Dahlmann, B., et al. (2021) · European Eating Disorders Review · doi:10.1002/erv.2822 · Cited by 99
A Pilot Study of Rhodiola rosea (Rhodax ® ) for Generalized Anxiety Disorder (GAD)
Bystritsky, A., Kerwin, L. E., & Feusner, J. D. (2008) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2007.7117 · Cited by 127
“17 In addition, individuals who do respond to established treatment often experience troublesome side-effects that may interfere with their adherence.”
Self-citationGlue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119874457 · Cited by 98
“In conclusion, treatment-resistant anxiety disorders are a major clinical problem (Bystrisky, 2006), and ketamine may be an important therapeutic alternative for a population with high rates of treatment resistance and few alternative treatment options.”
BackgroundThe use of waitlists as control conditions in anxiety disorders research
Patterson, B., Boyle, M. H., Kivlenieks, M., & Van Ameringen, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.08.015 · Cited by 94
Anxiolytic-like effect of neuropeptide S in the rat defensive burying
Vitale, G., Filaferro, M., Ruggieri, V., Pennella, S., Frigeri, C., Rizzi, A., Guerrini, R., & Calò, G. (2008) · Peptides · doi:10.1016/j.peptides.2008.08.014 · Cited by 92
“pharmacotherapy; in fact, some of the untoward side effects of classical anxiolytic drugs are associated with dependence, interaction with alcohol, or sedation [5].”
Nishitani, N., Nagayasu, K., Asaoka, N., Yamashiro, M., Andoh, C., Nagai, Y., Kinoshita, H., Kawai, H., Shibui, N., Liu, B., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0254-y · Cited by 92
Worry is associated with impaired gating of threat from working memory.
Stout, D. M., Shackman, A. J., Johnson, J. S., & Larson, C. L. (2015) · Emotion · doi:10.1037/emo0000015 · Cited by 89
“Existing therapeutic strategies for anxiety and other emotional disorders are inconsistently effective or associated with significant adverse effects (Bystritsky, 2006), highlighting the importance of understanding worry’s neurocognitive underpinnings.”
Backgroundde Abreu Costa, M., D’Alò de Oliveira, G. S., Tatton-Ramos, T., Manfro, G. G., & Salum, G. A. (2019) · Mindfulness · doi:10.1007/s12671-018-1058-1 · Cited by 85
Women, anxiety and mood: a review of nomenclature, comorbidity and epidemiology
Alexander, J. L., Dennerstein, L., Kotz, K. J., & Richardson, G. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11s.s45 · Cited by 102
Intrinsic functional connectivity of the central extended amygdala
Tillman, R. M., Stockbridge, M. D., Nacewicz, B. M., Torrisi, S., Fox, A. S., Smith, J. F., & Shackman, A. J. (2017) · Human Brain Mapping · doi:10.1002/hbm.23917 · Cited by 98
“Existing treatments for anxiety disorders are inconsistently effective or associated with significant adverse effects (Bystritsky, 2006; Cloos & Ferreira, 2009; Craske et al., 2017; Cuijpers, Cristea, Karyotaki, Reijnders, & Huibers, 2016; James, James, Cowdrey, Soler, & Choke, 2015), highlighting the need to identify…”
BackgroundInfluentialSecond-generation antipsychotics for anxiety disorders
Depping, A. M., Komossa, K., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008120.pub2 · Cited by 86
Feldman, R., Vengrober, A., & Ebstein, R. P. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.6 · Cited by 85
Shackman, A. J., Stockbridge, M. D., Tillman, R. M., Kaplan, C. M., Tromp, D., Fox, A. S., & Gamer, M. (2016) · Journal of Experimental Psychopathology · doi:10.5127/jep.054015 · Cited by 91
“This is important because existing treatments are inconsistently effective or associated with significant adverse effects (Bystritsky, 2006; Griebel & Holmes, 2013; Insel, 2012).”
BackgroundAripiprazole in the Treatment of Depressive and Anxiety Disorders: A Review of Current Evidence
Pae, C., Serretti, A., Patkar, A. A., & Masand, P. S. (2008) · CNS Drugs · doi:10.2165/00023210-200822050-00002 · Cited by 85
“prolacpatients tend to be resistant to standard treatment.[4,5] tin increase) and hypercholesterolaemia, are also”
BackgroundTreatment-resistant panic disorder: clinical significance, concept and management
Chen, M., & Tsai, S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.001 · Cited by 80
“In this decade, several studies began to discuss and establish the concept of treatment-resistant panic disorder (Stein and Seedat 2004; Bystritsky 2006; Menezes, Fontenelle et al. 2007; Ammar, Naja et al. 2015).”
BackgroundInfluentialBeyond the Medial Regions of Prefrontal Cortex in the Regulation of Fear and Anxiety
Shiba, Y., Santangelo, A. M., & Roberts, A. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2016.00012 · Cited by 82
“For example, whilst selective serotonin reuptake inhibitors (SSRIs) are considered as the first-line pharmacological treatment for anxiety disorders and depression, up to 40% of patients are estimated to be partially or completely resistant to the treatment (Bystritsky, 2006; Ipser et al., 2006).”
BackgroundVollbehr, N. K., Bartels-Velthuis, A. A., Nauta, M. H., Castelein, S., Steenhuis, L. A., Hoenders, H. J. R., & Ostafin, B. D. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204925 · Cited by 69
“It is estimated that 30–40% of patients recover with standard treatment and another 30–40% can be considered partially improved [29, 30].”
BackgroundQuantitative proteomics for investigating psychiatric disorders
Filiou, M. D., Turck, C. W., & Martins‐de‐Souza, D. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201000060 · Cited by 69
“Moreover, current medication is not without side effects and/or requires weeks to exert its effects and not all patients respond to existing drug treatment [3].”
BackgroundWanmaker, S., Geraerts, E., & Franken, I. H. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.027 · Cited by 75
“Cuijpers et al., 2010). The cause of the inconsistency of results might be methodological issues, such as inadequate controls and measurements (Shipstead et al., 2010). Given the study of Onraedt and Koster (2014) who also failed to find an effect of WM on rumination, these results indicate that a stand-alone WM train…”
BackgroundResultAligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“They consisted of eight narrative reviews (Bakker, Van Balkom, & Stein, 2005; Bandelow et al., 2008; Bystritsky, 2006; Chen & Tsai, 2016; Holt & Lydiard, 2007; Lorenz, Jackson, & Saitz, 2010; Pollack, 2009; Starcevic, 2008), five systematic reviews (Barton et al., 2014; Cosci & Fava, 2013; Ipser et…”
BackgroundSingewald, N., Sartori, S. B., Reif, A., & Holmes, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109418 · Cited by 67
“The limitations of efficacy of current treatments becomes more marked over time, with significant rates of long-term relapse (Bystritsky, 2006; Solis et al., 2021), particularly in those people with comorbid conditions such as major depressive disorder (MDD) (Ginsburg et al., 2018; Hofmeijer-Sevink…”
BackgroundNaylor, M., Ridout, B., & Campbell, A. (2020) · Cyberpsychology Behavior and Social Networking · doi:10.1089/cyber.2019.0287 · Cited by 63
“Indeed, for some, the road is even more difficult, with Bystritsky 27 reporting that, of those that seek treatment for anxiety, 40 percent do not respond to standard treatments such as Selective Serotonin Reuptake In-hibitors (SSRIs) and Cognitive Behavioral Therapy (CBT).”
Fischer, S., & Cleare, A. J. (2017) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2017.02.007 · Cited by 71
“Currently, the most reliable predictors of non-response include the severity of anxiety disorders and their comorbidity with other mental disorders, especially personality disorders (Bystritsky, 2006).”
BackgroundBrief Intervention for Anxiety in Primary Care Patients
Roy-Byrne, P., Veitengruber, J. P., Bystritsky, A., Edlund, M. J., Sullivan, G., Craske, M. G., Welch, S. S., Rose, R., & Stein, M. B. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.02.080078 · Cited by 58
“Adding a benzodiazepine is one option especially useful when there is a prominence of residual anxious symptoms without residual depressive symptoms.(62) Alternatively, adding another antidepressant is useful and could include combining an SSRI with venlafaxine, or combining either agent with mirtazapine or a tricycli…”
BackgroundSelf-citationHageman, S. B., van Rooijen, G., Bergfeld, I. O., Schirmbeck, F., de Koning, P., Schuurman, P. R., & Denys, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13276 · Cited by 56
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56
“Analyses are presented in three sections: (1) acute efficacy, safety, and tolerability responses in controlled studies; (2) acute dose-response data; and (3) maintenance treatment.”
BackgroundChen, X., van Gerven, J., Cohen, A. F., & Jacobs, G. E. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0185-5 · Cited by 60
Shen, E., Jiang, Y., Javidfar, B., Kassim, B. S., Loh, Y. E., Ma, Q., Mitchell, A., Pothula, V., Stewart, A. F., Ernst, P., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.144 · Cited by 54
Kumar, K. K., Appelboom, G., Lamsam, L. A., Caplan, A. L., Williams, N., Bhati, M. T., Stein, S. C., & Halpern, C. H. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319318 · Cited by 61
Treating treatment non-responders: A meta-analysis of randomized controlled psychotherapy trials
Gloster, A. T., Rinner, M. T. B., Ioannou, M., Villanueva, J., Block, V. J., Ferrari, G., Benoy, C., Bader, K., & Karekla, M. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2019.101810 · Cited by 53
Zheng, E. Z., Wong, N. M. L., Yang, A. S. Y., & Lee, T. M. C. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03003-w · Cited by 72
“Indeed, a signi fi cant portion of patients experiencing these symptoms do not respond well to conventional treatments [9, 10].”
BackgroundCompulsive Hoarding: An Interpretative Phenomenological Analysis
Kellett, S., Greenhalgh, R., Beail, N., & Ridgway, N. (2010) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465809990622 · Cited by 72
“…to present a huge challenge to researchers and clinicians (Maier, 2004; Steketee and Frost, 2003), particularly in producing an evidenced-based biopsychosocial formulation of the disorder (Bystritsky, 2006) and the further development and thorough evaluation of targeted treatment approaches.”
BackgroundRifkin-Zybutz, R. P., Erridge, S., Holvey, C., Coomber, R., Gaffney, J., Lawn, W., Barros, D. A. R., Bhoskar, U., Mwimba, G., Praveen, K., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06399-3 · Cited by 53
“Whilst these treatments are effective, around 50% of individuals will not respond to first-line therapy and up to 30% will fail to respond to multiple medications (Ansara 2020; Bystritsky 2006).”
BackgroundFaye, C., Hen, R., Guiard, B. P., Denny, C. A., Gardier, A. M., Mendez‐David, I., & David, D. J. P. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.08.009 · Cited by 54
Selective Mitochondrial Targeting Exerts Anxiolytic Effects In Vivo
Nußbaumer, M., Asara, J. M., Teplytska, L., Murphy, M. P., Logan, A., Turck, C. W., & Filiou, M. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.341 · Cited by 56
Resistance exercise training among young adults with analogue generalized anxiety disorder
Gordon, B. R., McDowell, C. P., Lyons, M., & Herring, M. P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.020 · Cited by 66
Research Paper A narrative review exploring the effectiveness of Compassion-Focused Therapy
Beaumont, E., & Hollins Martin, C. J. (2015) · Counselling Psychology Review · doi:10.53841/bpscpr.2015.30.1.21 · Cited by 49
Behavioral extremes of trait anxiety in mice are characterized by distinct metabolic profiles
Filiou, M. D., Asara, J. M., Nußbaumer, M., Teplytska, L., Landgraf, R., & Turck, C. W. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.019 · Cited by 49
“…disorders is of particular importance as they constitute the most common psychiatric disorders with up to one third of the patients not responding to existing treatments (Bystritsky, 2006; Kessler et al., 2005) and no molecular biomarkers for diagnosis/therapeutics available (Filiou et al., 2011b).”
BackgroundDifferential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action
Andreasen, J. T., Fitzpatrick, C. M., Larsen, M., Skovgaard, L., Nielsen, S. D., Clausen, R. P., Troelsen, K. B., & Pickering, D. S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.01.001 · Cited by 50
Haaland, A. T., Vogel, P. A., Launes, G., Haaland, V. Ø., Hansen, B., Solem, S., & Himle, J. A. (2011) · Behaviour Research and Therapy · doi:10.1016/j.brat.2011.08.007 · Cited by 57
The DNA methylome in panic disorder: A case-control and longitudinal psychotherapy-epigenetic study
Ziegler, C., Grundner-Culemann, F., Schiele, M. A., Schlosser, P., Kollert, L., Mahr, M., Gajewska, A., Lesch, K.-P., Deckert, J., Köttgen, A., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0648-6 · Cited by 47
Zoogman, S., Goldberg, S. B., Vousoura, E., Diamond, M. C., & Miller, L. (2019) · Spirituality in Clinical Practice · doi:10.1037/scp0000202 · Cited by 41
“In addition, a significant percentage of anxiety patients experiences treat-ment-resistant anxiety that follows a chronic and debilitating course (Bystritsky, 2006; Pol-lack et al., 2008).”
BackgroundDomschke, K., Seuling, P. D., Schiele, M. A., Bandelow, B., Batelaan, N. M., Bokma, W. A., Branchi, I., Broich, K., Burkauskas, J., Davies, S. J. C., et al. (2024) · World Psychiatry · doi:10.1002/wps.21177 · Cited by 46
The role of cannabis in treating anxiety: an update
Ameringen, M. V., Zhang, J., Patterson, B. A., & Turna, J. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000566 · Cited by 48
“siveness to first-line interventions such as medications and cognitive behavioural therapies [4],”
BackgroundGoldstein Ferber, S., Shoval, G., Zalsman, G., Mikulincer, M., & Weller, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.680403 · Cited by 40
“In addition, treatment resistance or partial remission are prevalent (13, 14).”
BackgroundBürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173660 · Cited by 41
“This first study was followed by several other studies on anxiety disorders including agoraphobia / panic disorder [22,23], OCD [20,24–29], post-traumatic stress disorder [30–33], social anxiety disorder [34–37], and specific phobia [21,38,39].”
BackgroundInfluentialKim, S. Y., Jeon, S. W., Lee, M. Y., Shin, D., Lim, W., Shin, Y. C., & Oh, K. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.0078 · Cited by 46
Fortress, A. M., Smith, I. M., & Pang, K. C. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.009 · Cited by 39
“Approximately 30% of patients will be refractory to treatment (Bystritsky, 2006; Al-Harbi, 2012), demonstrating a need for alternative treatment options to current antidepressants.”
BackgroundGordon, B. R., McDowell, C. P., Lyons, M., & Herring, M. P. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.043 · Cited by 37
Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014) · Health Technology Assessment · doi:10.3310/hta18500 · Cited by 36
“It has been recommended that the assessment of remission and recovery in anxiety disorders includes an assessment of functional status.(38) Recognition of treatment resistance is further complicated by the frequent presence of symptoms of more than one anxiety disorder and the presence of a comorbid disorder that pote…”
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 47
“2,9 19 However, there are challenges in using standard clinical trial approaches to evaluate psychedelics, as they are unique from other classes of pharmaceuticals in that they significantly alter one’s thoughts, perceptions, and feelings in a time-limited fashion.”
The Dimensional Structure of Internalizing Psychopathology: Relation to Diagnostic Categories
Snyder, H. R., Silton, R. L., Hankin, B. L., Smolker, H. R., Kaiser, R. H., Banich, M. T., Miller, G. A., & Heller, W. (2022) · Clinical Psychological Science · doi:10.1177/21677026221119483 · Cited by 41
“Primary analyses used lifetime history of disorder, given that individuals who currently do not meet diagnostic criteria frequently continue to have elevated symptoms and risk for recurrence (e.g., Bystritsky, 2006; Fava et al., 2007), but we also included analyses with only current diagnoses.”
MethodSankhe, A. P., Dalal, K., Save, D., & Sarve, P. (2017) · Psychology Health & Medicine · doi:10.1080/13548506.2017.1290260 · Cited by 34
“Despite having many therapeutic agents that would benefit the individual psychiatric conditions, treatment failure or resistant cases have been reported to occur to an extent of 40% (Bystritsky, 2006).”
BackgroundInfluentialFiliou, M. D., & Turck, C. W. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00001-8 · Cited by 39
“Further, drug efficacy can be delayed by several weeks, and the resistance to treatment is common in a substantial number of patients (Bystritsky, 2006).”
BackgroundConverging Prefronto-Insula-Amygdala Pathways in Negative Emotion Regulation in Marmoset Monkeys
Shiba, Y., Oikonomidis, L., Sawiak, S. J., Fryer, T. D., Hong, Y. T., Cockcroft, G. J., Santangelo, A. M., & Roberts, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.016 · Cited by 34
Common and dissociable effects of oxytocin and lorazepam on the neurocircuitry of fear
Kreuder, A., Scheele, D., Schultz, J., Hennig, J., Marsh, N., Dellert, T., Ettinger, U., Philipsen, A., Babasiz, M., Herscheid, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920147117 · Cited by 27
“Considering the adverse effects of BZDs and the considerable number of patients with treatment-resistant anxiety (9), new compounds that target and modulate the neurocircuitry of fear are needed.”
BackgroundKatzman, M. A. (2011) · Journal of Affective Disorders · doi:10.1016/s0165-0327(11)70004-0 · Cited by 39
“Many anxiety patients – indeed more than half – fail to adequately respond to antidepressant therapy (Brown et al., 1996; Yonkers et al., 1996; Thase, 2003; Adson et al., 2005; Worthington et al., 2005; Bystritsky, 2006; Hoge et al., 2008).”
BackgroundResultReview: Experimental models for Barrett's esophagus and esophageal adenocarcinoma
Garman, K. S., Orlando, R. C., & Chen, X. L. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00509.2011 · Cited by 32
Patterson, B. A., & Ameringen, M. V. (2016) · Depression and Anxiety · doi:10.1002/da.22525 · Cited by 41
“and society.[3] Standard first-line treatments for anxiety disorders include antidepressants such as serotonin reuptake inhibitors (SRIs) as well as cognitive behavioral therapy (CBT).”
BackgroundGould, R. L., Wetherell, J. L., Kimona, K., Serfaty, M. A., Jones, R., Graham, C. D., Lawrence, V., Livingston, G., Wilkinson, P., Walters, K., et al. (2021) · Age and Ageing · doi:10.1093/ageing/afab059 · Cited by 33
“…may seem high, they are unsurprising given that medical and psychiatric comorbidities are associated with poor treat-ment response in anxiety disorders [39] and strong associations have been reported between GAD and suicidal ideation, even after controlling for psychiatric comorbidity [40–42].”
BackgroundStill waiting for predictive biomarkers in Barrett's oesophagus
Moyes, L. H., & Going, J. J. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200084 · Cited by 31
Coulombe, S., Radziszewski, S., Meunier, S., Provencher, H. L., Hudon, C., Roberge, P., Provencher, M. D., & Houle, J. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.00584 · Cited by 38
“…treatments, which, although efficient, are limited by the fact that not all people respond positively to antidepressants or psychotherapy (Bystritsky, 2006; Lanouette and Stein, 2010; Berlim et al., 2015), and that several of them relapse (Boland and Keller, 2009; Boschen et al., 2009)…”
BackgroundBallı, T., Metin, B., Tülay, E. E., Tan, O., Sayar, G. H., Taş, C., Arıkan, M. K., & Tarhan, N. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.11.063 · Cited by 32
“The mainstay of the pharmacological treatment of OCD is clomipramine or selective serotonin reuptake inhibitors (SSRIs), which yield a response in about 50% of patients (Bystritsky, 2006; Jenike, 2004; Pallanti et al., 2002).”
BackgroundSustained Modulation of Deep Brain Circuits with Focused Ultrasonic Waves
Webb, T. D., Wilson, M. G., Odéen, H., & Kubanek, J. (2022) · Brain stimulation · doi:10.1016/j.brs.2023.04.012 · Cited by 35
de Menezes, G. B., Fontenelle, L. F., Mululo, S. C. C., & Versiani, M. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000600004 · Cited by 33
Zumbido e ansiedade: uma revisão da literatura
da Rosa, M. R. D., Almeida, A. A., Pimenta, F. C. F., Silva, C. G., Lima, M. A. R., & Diniz, M. D. F. F. M. (2012) · Revista CEFAC · doi:10.1590/s1516-18462012005000009 · Cited by 29
Increased Anxiety and Anhedonia in Female Rats Following Exposure to Altitude
Sheth, C. S., Ombach, H. J., Olson, P. R., Renshaw, P. F., & Kanekar, S. (2018) · High Altitude Medicine & Biology · doi:10.1089/ham.2017.0125 · Cited by 28
“The resulting societal burden involves direct costs of more than $42 billion each year (Bystritsky, 2006), suggesting an urgent need for research toward finding potential therapeutic targets.”
Lu, H., Cao, L. L., Ballout, F., Belkhiri, A., Peng, D., Chen, L., Chen, Z., Soutto, M., Wang, T. C., Que, J., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-329455 · Cited by 31
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. W. (2023) · Ochsner Journal · doi:10.31486/toj.23.0076 · Cited by 34
“14,17,18 Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are first-line pharmacologic agents for the treatment of anxiety disorders, 19 but some patients do not respond adequately to treatment with these agents and may develop a…”
BackgroundBowyer, L., Wallis, J., & Lee, D. (2013) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465813000362 · Cited by 28
Dèttore, D., Pozza, A., & Coradeschi, D. (2013) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2013.04.002 · Cited by 31
Self-stigma and treatment effectiveness in patients with anxiety disorders – a mediation analysis
Ocisková, M., Praško, J. P., Vrbová, K., Kasalová, P., Holubová, M., Grambal, A., & Machu, K. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s152208 · Cited by 36
“At the same time, only ~60% of anxiety disorder patients react significantly to the standardized treatments.(20) Ranging from generalized anxiety disorder(21) and social phobia(22) to panic disorder and agoraphobia,(23) all anxiety disorders show a similar pattern of commonly insufficient treatment results.”
Fischer, S., King, S., Papadopoulos, A., Hotopf, M., Young, A. H., & Cleare, A. J. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12970 · Cited by 27
“A number of studies have identified illness chronicity, severity and comorbidity with other mental disorders as the most promising candidates to predict non-responses (4, 5).”
BackgroundSchiele, M. A., Kollert, L., Lesch, K.-P., Arolt, V., Zwanzger, P., Deckert, J., Ziegler, C., & Domschke, K. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.131 · Cited by 26
Metadata
- Authors
- Bystritsky, A.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Bystritsky, A
- ORCID
- Bystritsky, A
- Venue
- Molecular Psychiatry
- Published
- 2006-07-18
- Volume
- 11
- Issue
- 9
- Pages
- 805-814
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2004241099
- Cited by
- 289
- References
- 88
- Citations by year
- 2026: 14 · 2025: 24 · 2024: 31 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 10 · 2019: 22 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 10 · 2014: 10 · 2013: 8 · 2012: 4
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- anxiety disorders, treatment resistance, serotonin reuptake inhibitors, cognitive behavioral therapy, residual symptoms, suicide attempts, quality of life, chronic anxiety, biological factors, social factors
- MeSH terms
- Anxiety Disorders, Humans, United States, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.